Initial Experience with Surpass Evolve Flow Diverter in the Treatment of Intracranial Aneurysms

Background and Purpose The principle of flow diversion has revolutionized the treatment of brain aneurysms. In this study, we report our experience of the new Surpass Evolve (SE) flow diverter in the treatment of intracranial aneurysms. Material and Methods Patients were treated with the SE as first-line therapy between May 2019 and June 2020 at 2 experienced institutions. Inclusion criteria were wide-necked, blister-like, or fusiform/dissecting aneurysms in the anterior and posterior circulation. Primary endpoint was technical success defined as favorable navigation to the target vessel and successful deployment of the SE. Secondary endpoints were favorable aneurysm occlusion defined as O'Kelly Marotta (OKM) scale C1-3 + D on follow-up, procedure-related complications and retreatment. Results A total of 46 aneurysms in 42 patients were treated with 57 SE flow diverters. Median aneurysm size was 6.6 mm (IQR 4.0-12.2 mm) with a median neck width of 4 mm (IQR 2.2-5.4 mm). On admission, 6 (13%) aneurysms were ruptured and 41 (89%) were located in the anterior circulation. The primary endpoint was reached in 96%. Median follow-up was 116 days (IQR 92-134 days) and available for 36/46 (78%) aneurysms. Favorable aneurysm occlusion was seen in 31/36 (86%) aneurysms and 27/36 (75%) were occluded completely. Parent artery occlusion appeared in 3 (3%) patients on follow-up and 2 aneurysms (6%) required additional treatment due to insufficient closure. Conclusion The new SE flow diverter is safe and seems to be effective with promising occlusion rates at short-term follow-up.

Automated summary

The study reported the experience of using the new Surpass Evolve (SE) flow diverter in treating intracranial aneurysms. Treatments were performed on 46 aneurysms in 42 patients, with results showing that the new SE flow diverter is safe and effective at short-term follow-up.